lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
==== Set and setting and moderating factors ==== The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly called set and setting. In the early 1960s, Timothy Leary and his Harvard colleagues investigated the role of set and setting in psilocybin's effects. They administered the drug to 175 volunteers (from various backgrounds) in an environment intended to be similar to a comfortable living room. 98 of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Those who had experience with psilocybin reported more pleasant experiences than those for whom the drug was novel. Group size, dose, preparation, and expectancy were important determinants of the drug response. In general, those in groups of more than eight felt that the groups were less supportive and their experiences less pleasant. Conversely, smaller groups (fewer than six) were seen as more supportive and reported more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens suggestibility, making a user more receptive to interpersonal interactions and environmental stimuli. These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dose, set, and setting are fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.
=== Financial markets and housing === Oil prices did not experience a surge, which had been normal with previous conflicts in oil-producing regions; prices increased 1% as of 5 January 2026. The reason is believed to be that Venezuela only represents 1% of the global oil supply and high oil production by other producers, including the United States, Saudi Arabia, and Brazil. The stock prices of companies that could become involved in Venezuela without spending money, such as oilfield service companies SLB and Halliburton, and refiners Valero Energy and Marathon Petroleum, surged on 5 January 2026. Some oil companies also saw increases, such as ExxonMobil and ConocoPhillips. Bonds issued by the Venezuelan government and the state oil company PDVSA surged by 30%. Venezuela's bonds went into default in 2017 and doubled in price during the escalating tensions in 2025. Housing prices in Caracas rose from 20% to 50%. In touristic sites like Margarita Island the housing prices rose up to 80%. Some listing were paused waiting for a stabilization of the economy.
==== Tissue engineering ==== Cells are very sensitive to nanotopographical features, so optimization of surfaces in tissue engineering has pushed towards implantation. Under appropriate conditions, a carefully crafted 3-dimensional scaffold is used to direct cell seeds toward artificial organ growth. The 3-D scaffold incorporates various nanoscale factors that control the environment for optimal and appropriate functionality. The scaffold is an analog of the in vivo extracellular matrix in vitro, allowing for successful artificial organ growth by providing the necessary, complex biological factors in vitro.
Functional KORs are present on nerve terminals of both oxytocin and vasopressin neurons in the rat neurohypophysis, where agonists inhibit potassium-evoked hormone release. Both dynorphin1-8 and (1–17) suppress stimulated oxytocin release from isolated neurosecretory endings, with effects on the initial and secondary peaks of hormone secretion, while exerting no influence on vasopressin release under similar conditions. These interactions extend to plasma hormone levels, where KOR agonists decrease circulating oxytocin concentrations, while antagonists increase oxytocin release, suggesting that KOR signaling mediates negative regulation of oxytocin secretion during stress or physiological challenges.
Sources: en.wikipedia.org
Ken Levine and other members of Looking Glass Studios founded Irrational Games in 1997. Their first game was System Shock 2, a sequel to Looking Glass's System Shock, and was a critical, but not commercial, success. Levine had attempted to pitch a sequel to System Shock 2 to Electronic Arts, but the publisher rejected the idea based on System Shock 2's disappointing sales. Irrational developed other games, including Freedom Force, Tribes: Vengeance, the canceled title Deep Cover, and The Lost which was never released due to legal complications. The wanted to return to a more free-form game with strong narrative in the same style as System Shock 2, feeling there was more to do with some of the concept of that game. At the same time, they were mindful of making a successor that was more accessible to a wider variety of players. "We recognized that there were things in System Shock 2 that were holding it back, that were excessively complicated, that were opaque or hard for people to understand or that they simply didn't like," Irrational co-founder Jonathan Chey recalled. By 2002, the team had come up with a core gameplay mechanic based on three groups: drones that would carry a desirable resource, protectors that would guard the drones, and harvesters that would attempt to take the resource from the drones. These groups would eventually become the Little Sisters, Big Daddies, and Splicers in the final game. They began working on a setting to pitch the idea to publishers. A 2002 demonstration version was based on the Unreal Engine 2 for the Xbox.
=== Bite treatment === First aid involves the application of an ice pack to control inflammation and prompt medical care. If it can be easily captured, the spider should be brought with the patient in a clear, tightly closed container so it may be identified by an arachnologist; if there is no specimen at all, then confirmation by an expert is impossible. Routine treatment should include immobilization of the affected limb, application of ice, local wound care, and tetanus prophylaxis. Many other therapies have been used with varying degrees of success, including hyperbaric oxygen, dapsone, antihistamines (e.g., cyproheptadine), antibiotics, dextran, glucocorticoids, vasodilators, heparin, nitroglycerin, electric shock, curettage, surgical excision, and antivenom. In almost all cases, bites are self-limited and typically heal without any medical intervention. Outpatient palliative care following discharge often consists of a weak or moderate strength opioid (e.g. codeine or tramadol, respectively) depending on pain scores, an anti-inflammatory agent (e.g. naproxen, cortisone), and an antispasmodic (e.g. cyclobenzaprine, diazepam), for a few days to a week. If the pain or spasms have not resolved by this time, a second medical evaluation is generally advised, and differential diagnoses may be considered.
=== Partner proteins === Assembly of the eIF4F complex is inhibited by proteins known as eIF4E-binding proteins (4E-BPs), which are small heat-stable proteins that block cap-dependent translation. Non-phosphorylated 4E-BPs interact strongly with eIF4E thereby preventing translation; whereas phosphorylated 4E-BPs bind weakly to eIF4E and thus do not interfere with the process of translation. Furthermore, binding of the 4E-BPs inhibits phosphorylation of Ser209 on eIF4E. Of note, 4E-BP1 is found in both the nucleus and the cytoplasm, indicating that it likely modulates nuclear eIF4Es functions of eIF4E as well. A recent study showed that 4E-BP3 regulated eIF4E dependent mRNA nucleo-cytoplasmic export. There are also many cytoplasmic regulators of eIF4E that bind to the same site as 4E-BP1. Many other partner proteins has been found that can both stimulate or repress eIF4E activity, such as homeodomain containing proteins, including HoxA9, Hex/PRH, Hox 11, Bicoid, Emx-2 and Engrailed 2. While HoxA9 promotes mRNA export and translation activities of eIF4E, Hex/PRH inhibits nuclear functions of eIF4E. The RNA helicase DDX3 directly binds with eIF4E, modulates translation, and has potential functions in P-bodies and mRNA export. RING domains also bind eIF4E. The promyelocytic leukemia protein PML is a potent suppressor of both the nuclear RNA export and oncogenic activities of eIF4E whereby the RING domain of PML directly binds eIF4E on its dorsal surface suppressing eIF4E's oncogenic activity; and moreover a subset of PML and eIF4E nuclear bodies co-localize.
Investigators have access to internationally recognized expertise in aging biology, comparative pathology, geriatric physiology, metabolism, pharmacology, molecular biology, and biostatistics, as well as state-of-the-art core facilities through the Nathan Shock Center of Excellence in the Basic Biology of Aging and the Claude D. Pepper Older Americans Independence Center. This integrated environment enables comprehensive mechanistic investigations that complement lifespan studies, allowing researchers to determine not only whether an intervention is effective, but also how it influences the biological processes underlying aging. The Interventions Testing Program also provides exceptional opportunities for scientific collaboration and investigator development. Faculty, postdoctoral fellows, and trainees participate in multidisciplinary research teams that span basic biology, translational science, pathology, pharmacology, and bioinformatics. Through participation in experimental design, animal studies, data analysis, and dissemination of findings, trainees gain firsthand experience conducting rigorous, large-scale preclinical aging research. These opportunities are further strengthened through integration with the Barshop Institute's NIH-funded Biology of Aging Training Program (T32), providing comprehensive education in experimental geroscience and translational aging research.
1995: British geomorphologist Marjorie Sweeting published the first comprehensive Western account of China's karst, entitled Karst in China: its Geomorphology and Environment. 1995: Israeli-Canadian mathematical biologist Leah Keshet became the first female president of the international Society for Mathematical Biology. 1995: British geochemist Jane Plant became the first female deputy director of the British Geological Survey. 1995: Inspectors from the United Nations Special Commission discovered that Iraqi microbiologist Rihab Taha, nicknamed "Dr. Germ", had been overseeing a secret 10-year biological warfare development program in Iraq. 1996: American planetary scientist Margaret G. Kivelson led a team that discovered the first subsurface, saltwater ocean on an alien world, on the Jovian moon Europa. 1997: Lithuanian-Canadian primatologist Birutė Galdikas received the Tyler Prize for Environmental Achievement for her research and rehabilitation work with orangutans. Her work with orangutans, eventually spanning over 30 years, was later recognized in 2014 as one of the longest continuous scientific studies of wild animals in history. 1997: Chilean astronomer María Teresa Ruiz discovered Kelu 1, one of the first observed brown dwarfs. In recognition of her discovery, she became the first woman to receive the Chilean National Prize for Exact Sciences. 1998: Nurse Fannie Gaston-Johansson became the first African-American woman tenured full professor at Johns Hopkins University. Late 1990s: Ethiopian-American chemist Sossina M. Haile developed the first solid acid fuel cell.
Sources: en.wikipedia.org
In Vietnamese cuisine, there are two varieties of glass noodles. The first, called bún tàu or bún tào, are made from mung bean starch, and were introduced by Chinese immigrants. The second, called miến or miến dong, are made from canna (Vietnamese: dong riềng), and were developed in Vietnam. These glass noodles are a main ingredient in the dishes: miến gà (chicken), miến lươn (eel), miến ngan (muscovy duck), and miến cua (crab). These glass noodles are sometimes confused with rice vermicelli (Vietnamese: bún) and arrowroot starch noodles (Vietnamese: arrowroot: củ dong, arrowroot starch: bột dong/bột hoàng tinh/tinh bột khoai mì).
=== Genetic factors === Genetic factors such as HLA-DR1B1, TRAF1, PSORS1C1 and microRNA 146a are associated with difficult-to-treat rheumatoid arthritis, other gene polymorphisms seem to be correlated with response to biologic modifying anti-rheumatic drugs (bDMARDs). The next one is the FOXO3A gene region been reported as associated with the worst disorder. The minor allele at FOXO3A summons a differential response of monocytes in RA patients. FOXO3A can provide an increase in pro-inflammatory cytokines, including TNFα. Possible gene polymorphism: STAT4, PTPN2, PSORS1C1 and TRAF3IP2 genes had been correlated with response to TNF inhibitors.
=== Diet === People who follow the prescribed dietary treatment from birth may (but not always) have no symptoms. Their PKU would be detectable only by a blood test. People must adhere to a diet low in Phe for optimal brain development. Since Phe is necessary to synthesize most proteins, it is required for appropriate growth, but levels must be strictly controlled.
==== Excitation-contraction coupling ==== Excitation contraction coupling is the process by which a muscular action potential in the muscle fiber causes the myofibrils to contract. This process relies on a direct coupling between the sarcoplasmic reticulum calcium release channel RYR1 (ryanodine receptor 1), and voltage-gated L-type calcium channels (identified as dihydropyridine receptors, DHPRs). DHPRs are located on the sarcolemma (which includes the surface sarcolemma and the transverse tubules), while the RyRs reside across the SR membrane. The close apposition of a transverse tubule and two SR regions containing RyRs is described as a triad and is predominantly where excitation–contraction coupling takes place. Excitation–contraction coupling occurs when depolarization of skeletal muscle cell results in a muscle action potential, which spreads across the cell surface and into the muscle fiber's network of T-tubules, thereby depolarizing the inner portion of the muscle fiber. Depolarization of the inner portions activates dihydropyridine receptors in the terminal cisternae, which are close to ryanodine receptors in the adjacent sarcoplasmic reticulum. The activated dihydropyridine receptors physically interact with ryanodine receptors to activate them via foot processes (involving conformational changes that allosterically activates the ryanodine receptors). As the ryanodine receptors open, Ca2+ is released from the sarcoplasmic reticulum into the local junctional space and diffuses into the bulk cytoplasm to cause a calcium spark.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.